Medizinische Universität Graz - Research portal
Navigation/Search
- Researchers
- Institutions
- Projects
- Publications
- Partners
- Sponsors
- Equipment
- Knowhow
- Fields of Research
"Faces" of the day:
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Innocenti, T; Hanžel, J; Truyens, M; Lukaš, M; Gordon, H; Cremer, A; Molnár, T; Julsgaard, M; Onali, S; Todeschini, A; Nardone, OM; Noor, NM; Caprioli, F; Scaldaferri, F; Argyriou, K; Savarino, EV; Brinar, M; Hedin, CRH; Vela, González, M; Armuzzi, A; Blesl, A; Aratari, A; Quadarella, A; Parigi, TL; Bertani, L; Ferracane, C; Uzzan, M; Michalopoulos, G; De, Bernardi, A; Katsanos, K; Balestrieri, P; Piñero, G; Karmiris, K; Casbas, AG; Nikolic, S; Felice, C; Pugliese, D; Pastras, P; Mocci, G; Pouillon, L; Mantzaris, GJ; Ramos, L; Casanova, MJ; Koutroubakis, IE; García, MJ; Lobaton, T; Dragoni, G, , Jaki-SEQ, Study, Group
.
Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class.
J Crohns Colitis. 2025;
Doi: 10.1093/ecco-jcc/jjaf188
PubMed
FullText
FullText_MUG
- Authors Med Uni Graz:
- Blesl Andreas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND AND AIMS: Evidence from rheumatology supports a within-class treatment switch for JAK-inhibitors (JAKi), but data in ulcerative colitis (UC) remain limited. We aimed to assess the effectiveness and safety of initiating a second JAKi in patients with UC previously treated with another JAKi. METHODS: We conducted a multicentre retrospective study, including patients with UC starting a second JAKi after prior JAKi exposure. The primary endpoint was week 12 steroid-free clinical remission (SFCR-rectal bleeding subscore = 0, stool frequency subscore ≤ 1, and no steroids). RESULTS: We included 243 patients [median follow-up: 38 (21-57) weeks]. At weeks 12, 26, and 52, SFCR was achieved in 116/243 (48%), 120/243 (49%), and 69/243 (28%), respectively. Secondary loss of response to the first JAKi was associated with higher SFCR at week 12 compared to primary failure (OR = 1.92, 95%CI = 1.11-3.30, p = 0.02). Higher baseline disease activity (OR = 0.68, 95%CI = 0.68-0.55, p < 0.01) and steroid use (OR = 0.23, 95%CI = 0.13-0.42, p < 0.01) had lower odds of week 12 SFCR. Endoscopic remission occurred in 22/243 (9%) (